240 related articles for article (PubMed ID: 35682589)
1. Cutaneous Melanomas: A Single Center Experience on the Usage of Immunohistochemistry Applied for the Diagnosis.
Ricci C; Dika E; Ambrosi F; Lambertini M; Veronesi G; Barbara C
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682589
[TBL] [Abstract][Full Text] [Related]
2. A rational approach to the follow-up of melanoma patients.
Garbe C
Recent Results Cancer Res; 2002; 160():205-15. PubMed ID: 12079215
[TBL] [Abstract][Full Text] [Related]
3. Expression of mitochondrial dynamics markers during melanoma progression: Comparative study of head and neck cutaneous and mucosal melanomas.
Soares CD; de Lima Morais TM; Mariano FV; Altemani A; Corrêa MB; Reis RRDD; Amorim LS; Ferreira SMS; de Almeida OP; Carlos R; Jorge J
J Oral Pathol Med; 2019 May; 48(5):373-381. PubMed ID: 30916813
[TBL] [Abstract][Full Text] [Related]
4. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
[TBL] [Abstract][Full Text] [Related]
5. Surgical margins for excision of primary cutaneous melanoma.
Zitelli JA; Brown CD; Hanusa BH
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):422-9. PubMed ID: 9308558
[TBL] [Abstract][Full Text] [Related]
6. The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.
Salmi S; Lin A; Hirschovits-Gerz B; Valkonen M; Aaltonen N; Sironen R; Siiskonen H; Pasonen-Seppänen S
BMC Cancer; 2021 May; 21(1):641. PubMed ID: 34051744
[TBL] [Abstract][Full Text] [Related]
7. Lymphatic invasion as a prognostic biomarker in primary cutaneous melanoma.
Xu X; Gimotty PA; Guerry D; Karakousis G; Elder DE
Methods Mol Biol; 2014; 1102():275-86. PubMed ID: 24258984
[TBL] [Abstract][Full Text] [Related]
8. Unusual histological variants of cutaneous malignant melanoma with some clinical and possible prognostic correlations.
Rongioletti F; Smoller BR
J Cutan Pathol; 2005 Oct; 32(9):589-603. PubMed ID: 16176296
[TBL] [Abstract][Full Text] [Related]
9. Disease progression in patients with thin cutaneous melanomas (tumour thickness < or = 0.75 mm): clinical and epidemiological data from the Tumour Center Munich 1977-98.
Schmid-Wendtner MH; Baumert J; Eberle J; Plewig G; Volkenandt M; Sander CA
Br J Dermatol; 2003 Oct; 149(4):788-93. PubMed ID: 14616371
[TBL] [Abstract][Full Text] [Related]
10. Thin Melanoma: A Generic Term Including Four Histological Subtypes of Cutaneous Melanoma.
Roncati L; Pusiol T; Piscioli F
Acta Dermatovenerol Croat; 2016 Dec; 24(4):169-174. PubMed ID: 28128089
[TBL] [Abstract][Full Text] [Related]
11. Noncutaneous melanoma have distinct features from each other and cutaneous melanoma.
Tas F; Keskin S; Karadeniz A; Dağoğlu N; Sen F; Kilic L; Yildiz I
Oncology; 2011; 81(5-6):353-8. PubMed ID: 22248874
[TBL] [Abstract][Full Text] [Related]
12. Desmoplasia and neurotropism. Prognostic variables in patients with stage I melanoma.
Baer SC; Schultz D; Synnestvedt M; Elder DE
Cancer; 1995 Dec; 76(11):2242-7. PubMed ID: 8635027
[TBL] [Abstract][Full Text] [Related]
13. Pathology of melanocytic lesions: new, controversial, and clinically important issues.
Scolyer RA; Thompson JF; Stretch JR; Sharma R; McCarthy SW
J Surg Oncol; 2004 Jul; 86(4):200-11. PubMed ID: 15221927
[TBL] [Abstract][Full Text] [Related]
14. High hERG1 expression in advanced melanoma.
Arcangeli A; Romoli MR; Boni L; Gerlini G; Tofani L; Urso C; Borgognoni L
Melanoma Res; 2013 Jun; 23(3):185-90. PubMed ID: 23524483
[TBL] [Abstract][Full Text] [Related]
15. Prognostic importance of mitochondrial markers in mucosal and cutaneous head and neck melanomas.
Soares CD; Morais TML; Carlos R; de Almeida OP; Mariano FV; Altemani A; de Carvalho MGF; Corrêa MB; Dos Reis RRD; Amorim LS; Jorge J
Hum Pathol; 2019 Mar; 85():279-289. PubMed ID: 30468799
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome.
Garg K; Maurer M; Griss J; Brüggen MC; Wolf IH; Wagner C; Willi N; Mertz KD; Wagner SN
Hum Pathol; 2016 Aug; 54():157-64. PubMed ID: 27107457
[TBL] [Abstract][Full Text] [Related]
17. c-myc is not useful as prognostic immunohistochemical marker in cutaneous melanoma.
Böni R; Bantschapp O; Müller B; Burg G
Dermatology; 1998; 196(3):288-91. PubMed ID: 9621133
[TBL] [Abstract][Full Text] [Related]
18. The impact of surgery on the course of melanoma.
Lejeune FJ
Recent Results Cancer Res; 2002; 160():151-7. PubMed ID: 12079209
[TBL] [Abstract][Full Text] [Related]
19. [Mucosal melanoma primary and metastatic cases with urogenital localization in our department].
Szabó B; Szűcs M; Horváth A; Székely E; Pánczél G; Liszkay G; Holló P; Wikonkál N; Nyirády P
Orv Hetil; 2019 Mar; 160(10):378-385. PubMed ID: 30829059
[TBL] [Abstract][Full Text] [Related]
20. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.
Gould Rothberg BE; Bracken MB; Rimm DL
J Natl Cancer Inst; 2009 Apr; 101(7):452-74. PubMed ID: 19318635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
